The aim of this study was to re-evaluate archived samples of canine soft tissue sarcomas (STSs) morphologically consistent with peripheral nerve sheath tumors (PNSTs). In each case, an immunohistochemical panel was applied, including α-SMA, calponin, desmin, S-100, GFAP, NSE and Olig2, in order to assess whether the phenotype was consistent with the tumor histological appearance. Additionally, the expression of EGFR, a marker with potential therapeutic implications in malignant PNSTs, was evaluated. Twenty-one tumors were included. Fourteen cases (66.7%) were positive for one or more muscular markers and were reclassifi ed as perivascular tumors (PWTs). A positive labeling for S-100 was observed in one tumor (4.8%), thus classifi ed as PNST. The other 6 tumors were generically classifi ed as poorly differentiated STSs. No unique histopathological feature was observed within the three groups. NSE and Olig2 labeling was aspecifi c and not useful for diagnostic purposes. GFAP was negative in all cases. Six cases (28.6%) were positive for EGFR, including the PNST. Even after the application of a wide immunohistochemical panel, distinguishing between PNSTs and PWTs remains a challenge. Finally, a subgroup of cases cannot be classifi ed based on light microscopy alone.
INTRODUCTION
Peripheral nerve sheath tumors (PNSTs) are a heterogeneous group of neoplasms originating from either Schwann cells, modifi ed Schwann cells, intraneural fi broblasts or perineural cells [1] [2] [3] .
Histologically, they are composed of spindle-shaped cells with ovoid, fusiform or serpentine nuclei, arranged in wavy bundles, nuclear palisades, whorls or storiform fascicles. This pattern is referred to as Antoni type A. In veterinary medicine the formation of Verocay bodies, characterized by a double row of palisading tumor cells, is rarely observed. Additionally, tumors may contain areas with loosely-packed tumor cells distributed in a fi brillary to mucinous matrix, referred to as Antoni type B pattern [4] . Based on cellular morphology, mitotic activity and tumor invasion, they are further subclassifi ed as benign (BPNST) or malignant (MPNST) [3, 5] .
PNSTs may occur also in soft tissue and, occasionally, in visceral organs [6] [7] [8] [9] .
Canine cutaneous peripheral nerve sheath tumors can generate diagnostic problems because of the histopathological similarities with other spindle cell tumors, including perivascular wall tumors (PWTs) and, less frequently, fi brosarcoma, leiomyosarcoma, myxosarcoma, and liposarcoma. Therefore, in diagnostic practice a range of potential differential diagnosis is usually provided or a generic diagnosis of soft tissue sarcoma (STS) is made [9, 10] .
The actual clinical advantage of sub-differentiating soft tissue sarcomas is questionable, due to their apparently similar biologic behavior. However, oversimplifi cation may represent an obstacle in the discovery of specifi c treatments. Research on the defi nite differentiation and prognostic factors for each STS is essential for the development of novel specifi c treatment strategies, including molecular targeted therapies.
Several immunohistochemical (IHC) markers have been tested in order to provide differential diagnosis for STSs. In particular, S-100, oligodendrocyte transcription factor 2 (Olig2), glial fi brillary acidic protein (GFAP), neuron specifi c enolase (NSE) and nerve growth factor receptor (NGFR) were suggested as PNST markers. Moreover, calponin, desmin and alpha-smooth muscle actin (α-SMA) have been proposed as PWT markers [9, [11] [12] [13] [14] . However, the results of such studies were poorly standardized and no defi nitive diagnostic criteria were established.
Recently, novel markers for therapeutic options have also been considered for MPNSTs. The epidermal growth factor receptor (EGFR), a 170-kDa receptor tyrosine kinase (RTK) protein, was found to be expressed in 80% of human MPNST and in most murine MPNST cell lines. Furthermore, it was also demonstrated that the EGFR-STAT3 signaling pathway promoted the formation of MPNST [15, 16] .
The aim of this study was to re-evaluate recently archived samples of canine cutaneous neoplasms initially diagnosed with STS-PNST based only on their morphology. In order to assess whether the phenotype was consistent with the tumor histological appearance a literature-based immunohistochemical panel was applied. Additionally, the expression of EGFR, a marker with potential therapeutic implications in MPNST, was assessed in canine STSs.
MATERIALS AND METHODS
A retrospective study was performed on archived cases submitted to the Pathology Service of the Department of Veterinary Medical Sciences, University of Bologna, between January 2011 and December 2014. Only canine cutaneous STS with a pre-existing diagnosis of PNST (as the primary diagnosis or among differential diagnoses) were included. None of them had previously undergone IHC analysis. The histologic diagnosis was made by different pathologists during their routine diagnostic activity. For each case, demographic information, including sex, age, breed, tumor location and tumor size were recorded.
Hematoxylin and eosin (HE) sections were re-evaluated separately by two pathologists (LM and RS) and graded according to Kuntz et al. (1997) [17] . Discordances were additionally re-examinated in order to achieve an agreement on the diagnosis.
For IHC analysis, a panel of 8 antibodies, including α-SMA, calponin, desmin, S-100, GFAP, NSE, Olig2 and EGFR, was applied to 4 μm serial tumor sections.
Endogenous peroxidase activity was blocked with 3% H 2 O 2 ; antigen retrieval is reported in Table 1 . Following overnight incubation at 4°C, the primary antibody was revealed by a commercial avidin-biotin-peroxidase kit (Vectastain Elite ABC Kit, PK-6100, Vector Laboratories, Burlingame, CA, USA); 3,3' diaminobenzidine (DAB Chromogen/Substrate Kit K001, DS-4011-A, Diagnostic BioSystems, Pleasanton, CA, USA) was used as chromogen. Canine intestine (α-SMA, desmin), canine mammary gland (calponin), canine brachial plexus nerve (S-100, Olig2, GFAP, NSE) and canine squamous cell carcinoma (EGFR) were used as positive controls. Negative controls were obtained by omitting the primary antibody. Tumors were defi ned as positive in the presence of immunolabeling in more than 10% of neoplastic cells according to Ko et al. (2014) [14] .
RESULTS

Demographic information
Twenty-one cases were included in the study. Nine dogs were mixed breed while 12 were purebred, the latter mostly represented by Boxer (n = 3), German shepherd (n=3) and Labrador retriever (n = 2). The mean age was 10.4 years (range, 4.5-16.5 years). Ten of these cases were represented by intact males and the remaining 11 case by females, 5 of which were spayed. Tumors were located in the forelimbs (n = 5); hindlimbs (n = 7), head (n = 1) and trunk (n = 8), including in the perivulvar (n = 1), mammary (n = 1) and paravertebral region (n = 1). The mean tumor diameter was 4.8 cm (range, 0.5-12 cm).
Histology
The microscopic examination revealed similar histologic appearance between all cases, with a variable alternation of highly-and poorly-cellular areas. The highly-cellular areas were composed by oval to spindle cells arranged irregularly in short bundles, palisades, storiform fascicles and concentric whorls. The poorly-cellular areas were characterized by fusiform neoplastic cells interspersed in loose fi brillary or myxoid matrix (Figure 1 ).
Two cases (9.5%) were classifi ed as grade I, 13 (61.9%) as grade II and the remaining 6 cases (28.6%) as grade III.
Immunohistochemistry
IHC results are detailed in Table 2 . Fourteen cases (66.7%) were positive for one or more muscular markers (α-SMA and calponin, 47.6% each; desmin, 14.3%). Of these tumors, none was positive for S-100, 5 (35.7%) were positive for both NSE and Olig2, and 4 (28.6%) were EGFR-positive. Within the 7 cases that resulted negative to the muscular markers, a positive labeling for S-100 was observed in one tumor (14.3%); 3 cases (42,8%) were positive for both NSE or Olig2, whereas 2 cases (28.6%) were EGFR-positive. All cases were negative to GFAP. Based on IHC results, the 14 tumors that resulted positive to muscular markers were classifi ed as PWTs (Figure 2) , the S-100 positive case was classifi ed as PNST ( Figure  3 ), whereas the other 6 tumors were classifi ed as poorly-differentiated STSs.
At the second histological evaluation, no unique morphological feature was observed within each of the three groups. All the 6 grade III tumors belonged to the PWT group, whereas the only PNST was grade I.
DISCUSSION
The distinction of PNSTs from perivascular wall tumors by histopathology is not currently based on clear morphological differences. Several authors suggest that the presence of nerve fi bers within the tumor may be a useful diagnostic indicator. Nevertheless, it is generally accepted that occasional small nerves may be seen in subcutaneous spindle cell tumors and that they are not necessarily related to the tumor itself [1, 4, 13, 14, 18] . Therefore, the true incidence of canine PNST and their biologic behavior are yet to be determined, due to poorly established diagnostic criteria. Currently, the degree to which STSs types behave similarly is unknown. Histological diagnosis is not essential for the clinical management of these tumors, however it could help understanding the prognosis. Most STSs are in acral location, and surgical excision at that level is intended to be marginal. Thus, understanding and differentiating their biologic behavior might be useful in the post-operative setting to evaluate the need for adjuvant treatments (e.g. radiotherapy or chemotherapy). The fi rst step in detecting potential differences is to defi ne methods for an accurate classifi cation. Although some recent studies improved the classifi cation of canine PWTs [11, 19] , there is still considerable overlap of histologic diagnosis between STS types.
The aim of the present study was to assess whether a histological re-evaluation, followed by a comprehensive immunohistochemical analysis, could be useful for obtaining a more accurate diagnosis in a subgroup of STSs consistent with a PNST morphology.
Although plenty of different antibodies have been tested in the past fi fteen years to help the identifi cation of canine PNSTs [9, [12] [13] [14] , no specifi c immunohistochemical marker has been identifi ed because of the heterogeneous data that emerged from these studies. For this reason a wide panel of reagents is generally used. According to the previously published studies, PNST appears to be primarily a "diagnosis of exclusion", with the fi rst distinguishing feature being the negativity to muscle cell markers. Indeed, immunoreactivity for α-SMA and desmin is a quite unusual fi nding in human PNSTs, and specifi cally it was described in one case out of 135 PNSTs [20] and 75 PNSTs [21] , while it was never documented for dogs [9, 12] . A study on PWT subclassifi cation reports positivity to muscular markers and negativity to S-100 and GFAP as reliable immunohistochemical features to distinguish PWTs from PNSTs [11] . In the present study, no overlapping was found between immunoreactivity to muscular markers and S-100, which led us to set reclassifi cation based only on those markers.
S-100 proteins are normally present in cells derived from the neural crest (Schwann cells and melanocytes). In human medicine, the expression of S-100 is used to differentiate between neural and non-neural origin spindle cell tumors [22] . In feline and equine PNSTs this marker has been proven to be useful in the diagnosis [23, 24] . However, S-100 immunoreactivity in canine MPNST may be unrewarding, likely because these neoplasms can be composed of various cell types other than Schwann cells, including perineural cells, or perineural or endoneural fi broblasts [12] [13] [14] . In our case series, tumor cells positive to S-100 were observed only in one case, possibly due to either a low PNST incidence or a poor sensitivity of this marker.
GFAP is an intermediate fi lament protein found in glial cells such as astrocytes and ependymal cells, in Schwann cells, enteric glial cells and satellite cells of human sensory ganglia [25] . In humans, GFAP expression is more frequently found in benign (33%) rather than MPNST (7%) [26] . In dogs, Chijiwa et al. (2004) reported a 35% GFAP expression (18% in MPNSTs and 67% in BPNSTs) [12] . Another study reports only one case of scattered GFAP expression within the cytoplasm of some large multinucleated cells [13] . Since no positive case was found in our series, we cannot provide a signifi cant contribution on the diagnostic utility of this marker.
NSE has also been used to demonstrate the neuroectodermal origin of neoplastic cells [3, 27] . However, the application of this marker has been limited because of the frequent nonspecifi c background staining. A similar tendency was observed in the present study, since a diffuse cytoplasmic positivity was also commonly detected in PWTs and in mesenchymal cells from the peritumoral stroma.
Olig2 is a marker of the oligodendroglial lineage and of some central nervous system progenitors [28] . In a recent study, Olig2 appeared to be a promising diagnostic marker for malignant PNSTs allowing the differentiation between PNSTs and PWTs with a positivity of 90% and 20%, respectively [9] . However, in the present study Olig2 results were quite disappointing, with extensive labelling of normal vessels walls and a 40% positivity recorded among PWTs.
The applied IHC panel did not allow a defi nitive differentiation between PWT and PNST in 6 cases. According to recent studies a small subgroup of PWTs with equivocal morphology and lack of specifi c immunohistochemical markers may exist, so that in the case of extensive immunohistochemical negativity a defi nitive diagnosis may not be reached. In order to provide clarity, further IHC studies should be performed in the presence of a defi nitive diagnosis based on ultrastructural investigation [29] .
Among other neural markers that have not been applied in the present study, NGFR and protein gene product 9.5 (PGP 9.5) may be worth further consideration [9] . Additionally, because Schwann cells differ from most PWT cells for the presence of a basal membrane, laminin and collagen IV have been proposed as PNST markers. Nevertheless, their sensitivity is lower in MPNSTs, where the basal lamina may be scant and focal, and positivity is limited to the tumors with a primary Schwann cell component [13] . Among PWTs, also glomus tumors have a basal lamina [4] .
Recently, several growth factors have been tested on canine PWTs in order to propose alternative therapeutic options for these tumors. The pathways with the highest expression were those mediated by RTK, including VEGFR, PDGFRβ and FGFR [19] . To the authors' knowledge, this is the fi rst time that EGFR expression is investigated in a cohort of canine STSs. The observed positivity in one fourth of the cases provides further evidence that multiple RTK blockade may represent a promising strategy for the local control of these tumors.
In summary, the IHC panel employed in the present study allowed reclassifi cation of 75% of the cases previously diagnosed as potential PNST by histology alone as PWTs, thereby showing a tendency to overdiagnose PNST. A PNST phenotype could only be confi rmed in 1 out of 21 cases. However, there may have been an underestimation due to the poor differentiation of the remaining 5 cases. Indeed, negativity to smooth muscle markers in the presence of a wavy cytoplasm, nuclear palisades, fascicles intersecting at sharp angles and presence of poorly cellular areas embedded in mucopolysaccaridic matrix, may suggest a diagnosis of PNST, even in
